Competitive Technologies, Aethlon Medical: Pain Relief Without the Pills

I failed chemistry in college. My ego says it was because I didn't apply myself. Still I feel grossly inept when it comes to analyzing biotech stocks. I bought Vanda Pharmaceuticals (VNDA) near $1 because of their strong cash position, then sold at $1.23 to get my money into something I understood better. If I had waited a week longer I could have sold over $12.

Nevertheless, two positions I intend to be very aggressive with are in the treatment business. Their products are not ingestible, yet both are proven to either reduce high levels of pain or significantly reduce viral loads. Neither stock is valued very highly, so shareholders get their own dose of pain with high volatility due to lack of interest.